BCM Industries (BCM) is a global leader in research and development in tissue engineering, cell regeneration and neural networks. We are commercializing our knowhow in neural tissue computing and autologous organ repair and replacement.
BCM is the home of advanced organ repair and replacement with the patient’s own DNA. Our Autologous Regenerative Tissue Replacement (ARTR™) organ repair technology is based on the 5StageAutograft™ procedure. A biopsy of the patient’s failing organ is the starting point. The harvested cells are reconditioned and grown on organic bedding (“scaffolding”). These new cells are grown in this tissue structure to the specifications of the surgeon.
When ready, that tissue structure is surgically inserted into the patient’s failing organ where the new cells integrate with the other cells and rapidly multiply. As this cell regeneration process proceeds the patient’s organ transitions to a healthy state. This organ repair process has completed stage one clinical trials on 8 kidney patients. Further clinical trials are scheduled for kidneys and the process is to be expanded to include the liver, lungs, and pancreas.
The next generation of this process is already in development under the name ARTR™ Plus+, enabling the growth of complete lab-based autologous replacement organs. In this transplant procedure, in parallel with the acquisition of the patient’s cells and the growth of the new cells, a same-sized organ from a deceased donor provides the structure. Just a size match suffices, no blood type or other criteria matter. The donated organ is sterilized at the cellular level, to remove all DNA from the donor. A completely sterilized organ structure is the result.
The newly grown autologous cells are now embedded into the sterilized organ and the reconstituted organ is used to replace the patient’s failing organ in a conventional organ transplant surgery. In all these ARTR™ procedures no follow-on anti-rejection drugs are required. To learn more, see the videos below or contact a BCM representative.
Tissue Computing Technology
The BCM tissue engineering technologies, experience, and skills are also at the core of our Tissue Operating Device (TOD™) computers, offering blinding processing speed and throughput, as well as massive data storage capacity, and lighting fast data transfers. The natural solution to enhanced processing is neuron populated live tissue, known as a neuron processor, or a Tissue Computer (TC).
To deliver an advanced tissue computer to commercial and consumer markets, BCM has announced the forthcoming availably of a family of TOD™ Models, all of which provide Tissue Computing, using live neurons. Tissue Computing will soon replace digital computing in many large data, video gaming, and complex processing applications. Click on the “TOD” tab to learn more. Also, see the video below or contact a BCM representative.
Benchmarking for neuron processing for large and complex processing tasks has shown performance gains of 1,000 times faster than a standard digital computer. To grasp the processing speed delivered by TOD™, if a standard digital computer requires 1,000 seconds (16.7 minutes) to complete a large processing task, TOD™ would complete that same task in 1 (ONE!) second.
By the time you finished clicking the enter key to start the processing, TOD™ would have delivered the results on your screen, or to your thumb or hard drive. That is the practical reality of 1,000 times faster processing.
Automated computing commenced with the vacuum tube, moved to silicon chips, and the next leap forward is Tissue Computing. Tissue Computing is the future of processing and will impact everyone and everything.
Kidney ARTR Procedure - Biopsy Phase
Liver Repair Procedure
Introduction to Physicians and Hospitals
Arriving Live Neural Network Tissue Computers - Briefing